Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors
Human Vaccines, Volume 7, No. 6, Year 2011
Notification
URL copied to clipboard!
Description
A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will affect immune responses elicited by a SeV vector-based vaccine. To quantify SeV-neutralizing antibodies (NAb) in human serum, a sensitive virus neutralization assay was developed using a SeV vector encoding green fluorescent protein. Samples from 255 HIV-uninfected subjects from Africa, Europe, United States and Japan, as well as from 12 confirmed hPIV-1-infected patients, were analyzed. SeV NAb titers did not vary significantly after serum was treated with receptor-destroying enzyme, indicating that non-specific hemagglutination inhibitors did not affect the assay sensitivity. A significant correlation was observed between hPIV-1 ELISA and SeV NAb titers. SeV NAb were detected in 92.5% subjects with a median titer of 60.6 and values ranging from 5.9-11.324. The majority had titers <1,000 with 71.7% <100 (<5 considered negative). There was no significant difference in titer or prevalence by gender, age range or geographic origin. However, African males had a lower titer than non-Africans of either gender (p = 0.007). Overall, the prevalence of SeV NAb is high and likely due to neutralization by cross-reactive hPIV-1 antibodies. Clinical trials will be needed to assess the influence of pre-existing SeV NAb on HIV-specific immune responses elicited by a SeV vaccine vector expressing HIV. © 2011 Landes Bioscience.
Authors & Co-Authors
Hara, Hiroto
Japan, Tsukuba
Dnavec Corporation
Hironaka, Takashi
Japan, Tsukuba
Dnavec Corporation
Inoue, Makoto
Japan, Tsukuba
Dnavec Corporation
Iida, Akihiro
Japan, Tsukuba
Dnavec Corporation
Shu, Tsugumine
Japan, Tsukuba
Dnavec Corporation
Hasegawa, Mamoru
Japan, Tsukuba
Dnavec Corporation
Nagai, Yoshiyuki
Japan, Yokohama
Riken Yokohama Institute
Falsey, Ann Regina
United States, Rochester
Rochester General Hospital
Kamali, Anatoli
Uganda, Entebbe
Uganda Virus Research Institute
Anzala, Aggrey Omu
Kenya, Nairobi
University of Nairobi
Sanders, Eduard Joachim
Kenya, Kilifi
Centre for Geographic Medicine Research
United Kingdom, Oxford
University of Oxford
Karita, Etienne
Rwanda, Kigali
Rwanda Zambia Hiv Research Group
Mwananyanda, Lawrence M.
Zambia, Lusaka
Rwanda Zambia Hiv Research Group and Emory University
Vasan, Sandhya
United States, New York
Aaron Diamond Aids Research Center
Lombardo, Angela
United States, New York
International Aids Vaccine Initiative
Parks, Christopher L.
United States, New York
International Aids Vaccine Initiative
Sayeed, Eddy
United States, New York
International Aids Vaccine Initiative
Krebs, Marietta
United States, New York
International Aids Vaccine Initiative
Cormier, Emmanuel G.
United Kingdom, London
Imperial College London
Ackland, James A.
United States, New York
International Aids Vaccine Initiative
Price, Matt A.
United States, New York
International Aids Vaccine Initiative
Excler, Jean Louis
United States, New York
International Aids Vaccine Initiative
Statistics
Citations: 27
Authors: 22
Affiliations: 12
Identifiers
Doi:
10.4161/hv.7.6.15408
e-ISSN:
15548619
Research Areas
Infectious Diseases
Study Design
Cross Sectional Study